July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
In Vivo examination in NZW rabbits of The CorNeat Kpro - a novel keratoprosthesis
Author Affiliations & Notes
  • Gilad Litvin
    Ein Tal, Tel Aviv, Israel
    CorNeat Vision, Israel
  • Footnotes
    Commercial Relationships   Gilad Litvin, CorNeat Vision (I), CorNeat Vision (P), CorNeat Vision (E)
  • Footnotes
    Support  CorNeat Vision Ltd. funded the GLP animal trial
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 4125. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Gilad Litvin; In Vivo examination in NZW rabbits of The CorNeat Kpro - a novel keratoprosthesis. Invest. Ophthalmol. Vis. Sci. 2019;60(9):4125.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : The CorNeat KPro is a novel artificial cornea. Here, we report the results of its implantation into animals, a procedure intended to prove safety and a requirement prior to human trials.
CorNeat KPros were implanted in 8 rabbits unilaterally and followed up for 6 months. Upon completion, progressive integrations with no inflammatory rejections were recorded.

Methods : Eight male NZW rabbits were subjected to a unilateral intraocular implantation of the CorNeat KPro, while the contralateral eye serves as an untreated control, all under Good Laboratory Practice guidelines.

Eight animals were clinically observed for a duration of 6-months to assess safety, during which the eyes are repeatedly monitored by slit-lamp biomicroscopy. At termination, eyes will be enucleated and evaluated histologically.

Results : To date, evidence shows progressive integration and cessation of inflammatory response. Eyes are all intact with no evident breach of integrity or leak of aqueous humor. Animals exhibit use of implanted eyes routinely. Some animals exhibit iatrogenic (surgically induced) Cataract.

Conclusions : The CorNeat KPro device safely integrates into native tissue. Results suggest great potential for its application in a range of human corneal diseases and injuries.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.


3 months post implantation- seemless tissue integration

3 months post implantation- seemless tissue integration


3 months following implantation

3 months following implantation


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.